GNT Pharma Reports Significant Improvements in Stroke Patients Treated with its pioneering Phase 3 Drug Nelonemdaz™
- Written by PR Newswire
![]() |
** IND submitted to the FDA showing significantly improved patient condition when administered within 70 minutes of arrival at the Emergency Room **
*Multinational Phase 3 Clinical Trial protocols confirmed and initiated with leading global stroke research centers *
SEOUL, South Korea, Dec. 11, 2024 /PRNewswire/ -- GNT Pharma Co. Ltd, a late-stage...















